Previous evidence has shown that EGFR-TKIs could diminish VEGF expression and inhibit tumor angiogenesis; when combined with antiangiogenic agents, they facilitate substantial survival benefits in advanced NSCLC patients [18–20]. This evidence concerns the gene EGFR and neoplasm.